GHK-Cu in copper transport, matrikine signalling and matrix metalloproteinase-2 expression in fibroblast culture
Ongoing research into nutritional and exercise interventions, as well as novel pharmacological agents such as myostatin/activin pathway inhibitors (243) or agents targeting the apelin pathway (244) holds promise for preserving lean mass and improving overall health in patients undergoing treatment with GLP-1 and dual GIP/GLP-1 receptor agonists
10.1016/j.biopsych.2009.09.033 132
The Study: Real-World Weight Loss Outcomes Researchers analyzed data from over 50,000 adults with obesity: 38,545 patients received a GLP-1 medication such as semaglutide or tirzepatide 12,540 patients underwent bariatric surgery, primarily gastric bypass or sleeve gastrectomy Key Findings : Surgery patients lost an average of 24% of their body weight over two years about 58 pounds
Baseline and periodic bone density scans can detect changes before they become serious
Some people find their appetite increases, or they notice small changes in their insulin sensitivity